Logo image of ADAG

ADAGENE INC-ADR (ADAG) Stock Fundamental Analysis

NASDAQ:ADAG - Nasdaq - US0053291078 - ADR - Currency: USD

1.77  -0.01 (-0.56%)

Fundamental Rating

2

Overall ADAG gets a fundamental rating of 2 out of 10. We evaluated ADAG against 572 industry peers in the Biotechnology industry. ADAG has a bad profitability rating. Also its financial health evaluation is rather negative. ADAG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADAG had negative earnings in the past year.
ADAG had negative earnings in each of the past 5 years.
In the past 5 years ADAG always reported negative operating cash flow.
ADAG Yearly Net Income VS EBIT VS OCF VS FCFADAG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -31.60%, ADAG is in the better half of the industry, outperforming 66.37% of the companies in the same industry.
The Return On Equity of ADAG (-56.28%) is better than 61.95% of its industry peers.
Industry RankSector Rank
ROA -31.6%
ROE -56.28%
ROIC N/A
ROA(3y)-35.83%
ROA(5y)-34.76%
ROE(3y)-56.61%
ROE(5y)-50.5%
ROIC(3y)N/A
ROIC(5y)N/A
ADAG Yearly ROA, ROE, ROICADAG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

ADAG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAG Yearly Profit, Operating, Gross MarginsADAG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

ADAG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADAG has been increased compared to 1 year ago.
The number of shares outstanding for ADAG has been increased compared to 5 years ago.
Compared to 1 year ago, ADAG has a worse debt to assets ratio.
ADAG Yearly Shares OutstandingADAG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ADAG Yearly Total Debt VS Total AssetsADAG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -3.52, we must say that ADAG is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ADAG (-3.52) is comparable to the rest of the industry.
ADAG has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
ADAG's Debt to Equity ratio of 0.15 is on the low side compared to the rest of the industry. ADAG is outperformed by 68.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -3.52
ROIC/WACCN/A
WACC8.87%
ADAG Yearly LT Debt VS Equity VS FCFADAG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

ADAG has a Current Ratio of 2.50. This indicates that ADAG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ADAG (2.50) is worse than 71.15% of its industry peers.
ADAG has a Quick Ratio of 2.50. This indicates that ADAG is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.50, ADAG is not doing good in the industry: 70.09% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 2.5
ADAG Yearly Current Assets VS Current LiabilitesADAG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.53% over the past year.
ADAG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -96.40%.
Measured over the past years, ADAG shows a very strong growth in Revenue. The Revenue has been growing by 64.36% on average per year.
EPS 1Y (TTM)14.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-309.45%
Revenue 1Y (TTM)-96.4%
Revenue growth 3Y195.77%
Revenue growth 5Y64.36%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 10.30% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.39%
EPS Next 2Y24.67%
EPS Next 3Y15.5%
EPS Next 5Y10.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADAG Yearly Revenue VS EstimatesADAG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ADAG Yearly EPS VS EstimatesADAG Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADAG. In the last year negative earnings were reported.
Also next year ADAG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAG Price Earnings VS Forward Price EarningsADAG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAG Per share dataADAG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ADAG's earnings are expected to grow with 15.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.67%
EPS Next 3Y15.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADAG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAGENE INC-ADR

NASDAQ:ADAG (2/7/2025, 1:38:56 PM)

1.77

-0.01 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29 2024-08-29
Earnings (Next)N/A N/A
Inst Owners24.76%
Inst Owner Change1.12%
Ins Owners3.25%
Ins Owner ChangeN/A
Market Cap78.36M
Analysts80
Price Target8.95 (405.65%)
Short Float %0.23%
Short Ratio0.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.87%
PT rev (3m)-16.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.05%
EPS NY rev (3m)5.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 96.06
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.02
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.6%
ROE -56.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.83%
ROA(5y)-34.76%
ROE(3y)-56.61%
ROE(5y)-50.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 2.5
Altman-Z -3.52
F-ScoreN/A
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)96.93%
Cap/Depr(5y)83.68%
Cap/Sales(3y)10.85%
Cap/Sales(5y)39.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-309.45%
EPS Next Y60.39%
EPS Next 2Y24.67%
EPS Next 3Y15.5%
EPS Next 5Y10.3%
Revenue 1Y (TTM)-96.4%
Revenue growth 3Y195.77%
Revenue growth 5Y64.36%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.42%
EBIT Next 3Y0.08%
EBIT Next 5YN/A
FCF growth 1Y42.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.46%
OCF growth 3YN/A
OCF growth 5YN/A